KoBioLabs

A Global Bio Company that Leads the Bio Industry

KoBioLabs

KoBioLabs

History

  • August 2020

    US FDA IND Approval of KBLP-001 phase 2 study

    June 2020

    KBLP-001 PhII study IND filing (US)

    April 2020

    KBLP-007 Non-IND human PoC study for ulcerative colitis initiated (KR)

    KBLP-002 Non-IND human PoC study for asthma initiated (KR)

    March 2020

    KBLP-002 PhI study HREC approval (AU)

  • October 2019

    KBLP-001 PhI study FIH dosing initiated (AU)

    ₩27b Pre-IPO funding completed

    February 2019

    Attracted ₩4b strategic investment from CJ CheilJedang Co., Ltd.

  • December 2018

    KBLF-001/KBLF-002 IRB approval of human study in Samsung Medical Center (KR)
    (Non-IND human PoC study for atopic dermatitis)

    November 2018

    KBLF-003 IRB approval of human study in Samsung Medical Center (KR)
    (Non-IND human PoC study for depression)

    Established KoBioLabs Australia Pty Ltd.

    May 2018

    Received the Ministry of Science and ICT Award

    Psychiatric program, selected as government sponsored project by MOTIE(Ministry of Trade, Industry and Energy)

  • July 2017

    ₩10b Series A funding closed

    Atopic dermatitis program, selected as government sponsored project by MOTIE(Ministry of Trade, Industry and Energy)

    Chronic kidney disease program, selected as government sponsored project by MSS(Ministry of SMEs and Startups)

  • July 2016

    C. diffinfection program, selected as government sponsored project by MSIP(Ministry of Science, ICT and Future Planning)

    March 2016

    ₩1.5b Pre-Series A funding closed

  • May 2015

    Corp R&D institute established

  • November 2014

    Certification of Venture Business

    August 2014

    Kobiolabs, Inc. founded, a spin-off from Microbiome Center at Seoul National University